宫颈癌不同体位调强放疗对周围正常组织的辐射剂量学研究

doi:10.13491/j.issn.1004-714x.2018.04.025

中国辐射卫生

2018, Vol. 27

Issue (4): 381-384 DOI: 10.13491/j.issn.1004-714x.2018.04.025

本期目录 | 过刊浏览 | 高级检索

宫颈癌不同体位调强放疗对周围正常组织的辐射剂量学研究

苗慧¹, 施林心¹, 白海生², 邵卫仙¹, 袁成¹, 刘亚洲¹, 孙苏平¹, 陈宏林¹, 罗举建¹, 惠华¹, 张文¹

1. 徐州市肿瘤医院, 江苏徐州 221000;
2. 新沂市中医医院

Dosimetric study on intensity-modulated radiotherapy with dissimilar position on peripheral normal tissues and organs of cervical cancer

MIAO Hui¹, SHI Linxin¹, BAI Haisheng², SHAO Weixian¹, YUAN Cheng¹, LIU Yazhou¹, SUN Suping¹, CHEN Honglin¹, LUO Jujian¹, HUI Hua¹, ZHANG Wen¹

1. Xuzhou Cancer Hospital, Xuzhou 221000 China;
2. Xinyi Hospital of Traditional Chinese Medicine

摘要
图/表
参考文献
相关文章 (1)

全文: PDF (869 KB) HTML ( )
输出: BibTeX | EndNote (RIS)

摘要目的探讨宫颈癌三维适形调强放射治疗（IMRT）中仰卧位和俯卧位对危及器官受照剂量的影响。方法选取14例宫颈癌术后调强放疗患者分别先后采取仰卧位（Supine）、俯卧位（Prone）CT模拟定位并勾画靶区及危及器官，完成IMRT计划设计，分别评估两个计划的靶区适形指数（CI）和均匀性指数（HI）及危及器官的剂量学参数。两种计划参数比较用配对t检验。结果 Supine IMRT和Prone IMRT两种放疗计划均能达到PTV剂量要求，两种计划相比，PTV在CI、HI上相近（P=0.211，0.190）；与仰卧位相比，俯卧位患者的小肠V40、小肠V50降低（P < 0.05），结肠V40、骨盆D max俯卧位较仰卧位也降低（P < 0.05），对直肠、膀胱、左右股骨头、脊髓、乙状结肠两种体位的剂量差异无统计学意义（P > 0.05）。结论宫颈癌患者行IMRT时采用俯卧位能降低小肠等器官的受照剂量，从而减少不良反应发生，具有临床应用价值。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	苗慧
	施林心
	白海生
	邵卫仙
	袁成
	刘亚洲
	孙苏平
	陈宏林
	罗举建
	惠华
	张文

关键词 ：宫颈肿瘤, 调强放射治疗, 体位, 危及器官

收稿日期: 2018-02-20

PACS:

R144.1

基金资助:江苏省卫生计生委科研课题项目（Y2015013）

通讯作者: 张文,E-mail:13615105270@163.com E-mail: 13615105270@163.com

作者简介: 苗慧(1977-),女,副主任医师,博士在读,从事肿瘤学放射治疗工作。

引用本文:

苗慧, 施林心, 白海生, 邵卫仙, 袁成, 刘亚洲, 孙苏平, 陈宏林, 罗举建, 惠华, 张文. 宫颈癌不同体位调强放疗对周围正常组织的辐射剂量学研究[J]. 中国辐射卫生, 2018, 27(4): 381-384.
MIAO Hui, SHI Linxin, BAI Haisheng, SHAO Weixian, YUAN Cheng, LIU Yazhou, SUN Suping, CHEN Honglin, LUO Jujian, HUI Hua, ZHANG Wen. Dosimetric study on intensity-modulated radiotherapy with dissimilar position on peripheral normal tissues and organs of cervical cancer. , 2018, 27(4): 381-384.

链接本文:

http://www.zgfsws.com/CN/10.13491/j.issn.1004-714x.2018.04.025 或 http://www.zgfsws.com/CN/Y2018/V27/I4/381

[1] Lyman JT.Complication probability as assessed from dose volume histograms[J].Rad Res,1985,104:S13-S19.
[2] Allemani C,Weir HK,Carreira H,et al.Global surveillance of cancer survival 1995-2009:analysis of individual data for 25676887 patients from 279 population-based registries in 67 countries(CONCORD-2)[J].Lancet,2015,385(9972):977-1010.
[3] 王静,许可葵,史百高,等.4374例宫颈癌患者预后及其影响因素分析[J].中国肿瘤,2014,23(4):281-288.
[4] Wang W,Meng Q,Hou X,et al.Efficacy and toxicity of image-guided intensity-modulated radiation therapy combined with dose-escalated brachytherapy for stage ⅡB cervical cancer[J].Oncotarget, 2017,8(61):102965-102973.
[5] Vandecasteele K,Makar A,Van den Broecke R,et al.Intensity-modulated arc therapy with cisplatin as neo-adjuvant treatment for primary irresectable cervical cancer.Toxicity,tumour response and outcome[J].Strahlenther Onkol, 2012,188(7):576-581.
[6] Du XX,Yang H,Zhang HJ,et al.Clinical study of intensity modulated radiotherapy and three-dimensional conformal radiotherapy with three-dimensional brachytherapy and concurrent chemotherapy for patients with advanced cervical cancer[J].Zhonghua Fu Chan Ke Za Zhi,2017,52(10):679-686.
[7] DU XL,Tao J,Sheng XG,et al.Intensity-modulated radiation therapy for advanced cervical cancer:a comparison of dosimetric and clinical outcomes with conventional radiotherapy[J].Gynecol Oncol,2012,125(1):151-157.
[8] Igdem S,Ercan T,Alco G,etal.Dosimetric comparison of intensity modulated pelvic radiotherapy with 3D conformal radiotherapy in patients with gynecologic malignancies[J].Eur J Gynaecol Oncol,2009,30(5):547-551.
[9] 庞皓文,邱杰,孙帅,等.宫颈癌调强放疗中直肠体积与位置变化及对吸收剂量影响[J].中华放射肿瘤学杂志,2012,21(3):258-261.
[10] Olofsen-van Acht M,van den Berg H,Quint S,et al.Reduction of Irradiated Small Bowel Volume and Accurate Patient Positioning by Use of A Bellyboard Device in Pelvic Radiotherapy of Gynecological Cancer Patients[J].Radiother Oncol,2001,59(1):87-93.
[11] Adli M,Mayr NA,Kaiser HS,et al.Does prone positioning reduce small bowel dose in pelvic radiation with intensity modulated radiotherapy for gynecologic cancer[J].Int J Radiat Oncol Biol Phys,2003,57:230-238.
[12] 邢晓汾,郑亚琴,臧志芳,等.子宫颈癌调强放射治疗中不同体位的计量学研究[J].肿瘤研究与临床,2010,22(2):115-117.
[13] 韩丽萍,孙晓慧,李元,等.宫颈鳞癌组织中PD-1和PD-L1的表达及其临床意义[J].中国妇幼保健,2016,(20):4290-4293.
[14] Lin Y,Zhai E,Liao B,et al.Autocrine VEGF signaling Promotes cell proliferation through a PLC-dependent pathway and modulates Apatinib treatment efficacy in gastric cancer[J].Oncotarget,2017,8(7):11990-12002.
[15] Zhang L,Chen Q,Hu J,et al.Expression of HIF-2α and VEGF in cervical squamous cell carcinoma and its clinical significance[J].Biomed Res Int,2016(2016):5631935-5631942.
[16] 刘伟,张建文.阿帕替尼对宫颈癌Hela细胞体外放射作用的研究[J].中国药业,2017,26(19):27-30.